NBI-1070770
DrugSuspension for oral administration
NCT Number: NCT06267846
To evaluate the efficacy, safety, and tolerability of NBI-1070770 compared to placebo on improving symptoms of depression in participants with major depressive disorder (MDD).
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Phase 2
Neurocrine Clinical Site, Little Rock, Arkansas, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Key Inclusion Criteria:
Participants must meet all of the following inclusion criteria:
Key Exclusion Criteria:
Participants will be excluded from the study if they meet any of the following criteria:
Note: Other inclusion/exclusion criteria may apply
Suspension for oral administration
Suspension for oral administration
Time frame: Baseline, Day 5
Time frame: Baseline, up to Day 49
Neurocrine Biosciences
Industry
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of NBI-1070770 in Adults With Major Depressive Disorder
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06001346
Behavior, Behavioral Symptoms
Ames, Iowa, United States
View Trial DetailsNCT06266390
Behavior, Behavioral Symptoms
Philadelphia, Pennsylvania, United States
View Trial DetailsNCT06282146
Anxiety Disorders, Behavior
Boston, Massachusetts, United States
View Trial DetailsNCT07017478
Behavior, Behavioral Symptoms
Chicago, Illinois, United States
View Trial Details